Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2022-10-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于公司2022年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a 2022 restricted stock incentive plan by 奥锐特药业股份有限公司. It details the investigation scope, procedures, findings, and conclusions about insider trading by persons aware of the incentive plan before its public disclosure. The document is a regulatory announcement about compliance and insider trading checks rather than a financial report, earnings release, or management discussion. It does not contain financial statements or performance data. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about insider trading and internal controls.
2022-10-17 Chinese
奥锐特药业股份有限公司2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 first extraordinary general meeting of shareholders of 奥锐特药业股份有限公司. It includes information about the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and meeting procedural details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and contains the full voting results, not just a notice of report publication or a brief announcement, so it is not an RPA or RNS. Therefore, the classification is DVA with high confidence.
2022-10-17 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司2022年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of a company's 2022 first extraordinary general meeting of shareholders. It details the legal compliance of the meeting process and the validity of the voting results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a formal legal opinion related to a shareholders' meeting, specifically focusing on the voting results and procedures. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the appropriate classification is DVA with high confidence.
2022-10-17 Chinese
奥锐特药业股份有限公司监事会关于公司2022年限制性股票激励计划激励名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the verification and disclosure of the list of incentive recipients under the company's 2022 restricted stock incentive plan. It includes details about the legal basis, the verification process, and confirmation that the incentive recipients meet regulatory requirements. The document is relatively short (1509 characters) and focuses on disclosure and verification related to a stock incentive plan, not the plan itself or detailed financial data. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement rather than a full report or financial statement.
2022-10-10 Chinese
奥锐特药业股份有限公司2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2022 First Extraordinary General Meeting" of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It contains detailed agenda, meeting procedures, and multiple proposals related to a 2022 restricted stock incentive plan. The content is clearly related to a shareholders' meeting, including voting procedures and legal opinions. There is no financial data or earnings information, nor is it an announcement of voting results. The document is a presentation of materials for the shareholders' meeting itself. Therefore, it fits the category of AGM Information (AGM-R). The document length (5322 characters) supports it being a full meeting material rather than a brief announcement.
2022-10-09 Chinese
奥锐特药业股份有限公司关于独立董事公开征集投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a public announcement by a company's independent director soliciting proxy voting rights from shareholders for an upcoming extraordinary general meeting (EGM) to be held on October 17, 2022. It details the voting agenda related to a 2022 restricted stock incentive plan, the procedures for shareholders to authorize the independent director to vote on their behalf, and includes an authorization form for proxy voting. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not a report but an announcement related to shareholder voting rights and proxy solicitation for a specific meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-09-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.